Aurobindo Pharma Limited has announced the opening of its buyback offer for up to 54,23,728 equity shares at a price of ₹1,475 per share, payable in cash. The aggregate consideration for the buyback amounts to ₹800,00,00,000, excluding transaction costs. The offer, which follows the tender offer route using the stock exchange mechanism, opened on April 23, 2026, and will close on April 29, 2026. The last date for receipt of completed tender forms and other specified documents by the registrar is April 29, 2026, on or before 5.00 PM IST.

The company has dispatched the letter of offer and tender form, along with the share transfer form dated April 21, 2026, through electronic means to all eligible shareholders holding equity shares as on the record date of April 17, 2026. Shareholders whose email IDs are registered with the company or depositories received these documents electronically. In accordance with Regulation 9(ii) of the Buyback Regulations, physical copies of the letter of offer will be dispatched by registered post, speed post, or courier upon request from eligible shareholders.

The entitlement ratio for eligible shareholders has been categorized into two segments. Small shareholders in the reserved category are entitled to 7 equity shares out of every 61 equity shares held on the record date. The general category for all other shareholders is entitled to 2 equity shares out of every 249 equity shares held on the record date. Shareholders can verify their entitlement by visiting the registrar's website and following the specified process, which involves selecting the company name, holding type, and entering relevant details such as folio number, DPID/Client ID, or PAN.

Axis Capital Limited has been appointed as the manager to the offer, while KFin Technologies Limited serves as the registrar to the offer. The letter of offer is available on the company's website, the registrar's website, and the manager to the buyback's website. The company has also published a corrigendum to the public announcement, revising the premium over the volume weighted average market price of the equity shares on BSE during the two weeks preceding the intimation date to 12.72% instead of the previously stated 13.18%. The buyback offer is being conducted under the Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018, as amended.

Aurobindo pharma Ltd. recorded a notable block trade on the National Stock Exchange (NSE), marking significant institutional trading activity in the pharmaceutical company's shares. The transaction involved substantial volume and value, indicating strong investor interest in the stock.

Block Trade Details

The block trade executed on NSE demonstrated considerable market participation with specific transaction parameters that highlight the scale of institutional involvement.

Transaction Significance

Block trades typically represent large-volume transactions executed outside the regular market to minimize price impact. Such transactions often involve institutional investors, mutual funds, or other large market participants seeking to buy or sell substantial quantities of shares.

The execution price of Rs. 1371.90 per share for this block trade provides insight into the institutional valuation of Aurobindo Pharma's stock during the transaction period. The substantial volume of 241,320 shares indicates significant institutional interest in the pharmaceutical company.

Market Impact

Block trades of this magnitude often reflect institutional portfolio adjustments or strategic investment decisions. The Rs. 33.11 crore transaction value represents a meaningful trading activity that could influence market sentiment and trading patterns for Aurobindo Pharma shares.